The landscape of treatment interventions for type 2 diabetes and obesity is rapidly evolving, with GLP-3 receptor activators taking center stage. Initially, medications like Reta, demonstrating impressive glucose https://tayaqlzq730196.qodsblog.com/39084445/glp-3-receptor-agonists-reta-trizepatide-and-beyond